Dicerna Pharmaceuticals Inc
DRNADelisted Dec 28, 2021- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001399529
Dicerna Pharmaceuticals Inc was delisted on Dec 28, 2021; its insiders filed their last Form 4 on Dec 29, 2021; 173 institutions reported holding it in 13F filings for Q3 2021, worth $1.28B in total; Maverick Capital was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 173
- Q3 2021, −29 vs. previous quarter
- 13F value
- $1.28B
- Reported value at the end of Q3 2021
- Superinvestors holding
- 1
- At the end of Q3 2021
Superinvestors holding DRNA, Q3 2021
1 superinvestor reports holding Dicerna Pharmaceuticals Inc on Form 13F. Percentages are the stock's share of each portfolio.
Maverick Capital
Lee Ainslie
0.3%
Dicerna Pharmaceuticals Inc's share of the portfolio
- Shares
- 1,310,530
- Value
- $26.4M
Latest insider trades
Open-market purchases and sales by Dicerna Pharmaceuticals Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 22, 2021 (view filing) | Nov 18 | 4 days | Brown Bob DChief Scientific Ofr., EVP R&D | SSale | −24.9K | $37.94 | −$946.1K | −98.9%267 after | |
| Sep 21, 2021 (view filing) | Sep 17 | 4 days | Brown Bob DChief Scientific Ofr., EVP R&D | SSale | −21.3K | $21.06 | −$447.5K | −98.8%267 after | |
| Sep 17, 2021 (view filing) | Sep 17 | Same day | Zeng LingChief Legal Officer & Sec'y | SSale | −1.33K | $21.47 | −$28.6K | −29.3%3.22K after | |
| Sep 17, 2021 (view filing) | Sep 17 | Same day | Aradhye ShreeramEVP & Chief Medical Officer | SSale | −2.06K | $21.47 | −$44.1K | −29.3%4.97K after | |
| Aug 10, 2021 (view filing) | Aug 10 | Same day | Fambrough DouglasPresident and CEO | PPurchase | +5.00K | $22.10 | +$110.5K | +13.1%43.2K after | |
| Aug 10, 2021 (view filing) | Aug 10 | Same day | Kozin Marc DDirector | PPurchase | +3.00K | $23.66 | +$71.0K | +90.0%6.33K after | |
| Aug 3, 2021 (view filing) | Aug 2 | 1 day | Brown Bob DChief Scientific Ofr., EVP R&D | SSale | −8.31K | $37.38 | −$310.7K | −27.9%21.5K after | |
| Jul 8, 2021 (view filing) | Jul 6 | 2 days | Weissman James BChief Operating Officer & EVP | SSale | −30.0K | $39.09 | −$1.17M | −65.2%16.0K after | |
| Jul 6, 2021 (view filing) | Jul 1 | 5 days | Brown Bob DChief Scientific Ofr., EVP R&D | SSale | −8.31K | $37.37 | −$310.6K | −27.9%21.5K after | 2 lots |
Top 10 13F holders, Q3 2021
The largest institutional positions in Dicerna Pharmaceuticals Inc at the end of Q3 2021; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| RTW Investments, LP | 7,582,396 | $152.9M | 2.31% | +60,537+0.8% | Added |
| BlackRock Inc. | 5,763,585 | $116.2M | 0.00% | −11,949−0.2% | Reduced |
| State Street Corp | 3,886,181 | $78.3M | 0.00% | +1,297,119+50.1% | Added |
| Vanguard Group Inc | 3,707,210 | $74.7M | 0.00% | +86,857+2.4% | Added |
| Bain Capital Life Sciences Investors, LLC | 3,080,237 | $62.1M | 3.85% | 00.0% | Unchanged |
| Price T Rowe Associates Inc | 2,682,596 | $54.1M | 0.01% | +699,671+35.3% | Added |
| Aquilo Capital Management, LLC | 2,456,595 | $49.5M | 11.66% | +643,203+35.5% | Added |
| Morgan Stanley | 1,736,277 | $35.0M | 0.00% | +624,188+56.1% | Added |
| JPMorgan Chase & Co | 1,542,476 | $31.1M | 0.00% | +110,950+7.8% | Added |
| Woodline Partners LP | 1,352,048 | $27.3M | 0.45% | +351,723+35.2% | Added |